CN116348106A - 卤代裸盖菇素衍生物及使用方法 - Google Patents

卤代裸盖菇素衍生物及使用方法 Download PDF

Info

Publication number
CN116348106A
CN116348106A CN202180067808.XA CN202180067808A CN116348106A CN 116348106 A CN116348106 A CN 116348106A CN 202180067808 A CN202180067808 A CN 202180067808A CN 116348106 A CN116348106 A CN 116348106A
Authority
CN
China
Prior art keywords
seq
nucleic acid
halogenated
alkyl group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180067808.XA
Other languages
English (en)
Chinese (zh)
Inventor
吉利恩·M·哈格尔
彼得·J·法基尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nvirick Biosciences Canada Co
Original Assignee
Nvirick Biosciences Canada Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80492287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN116348106(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nvirick Biosciences Canada Co filed Critical Nvirick Biosciences Canada Co
Publication of CN116348106A publication Critical patent/CN116348106A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/0102—Tryptophan synthase (4.2.1.20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202180067808.XA 2020-09-01 2021-09-01 卤代裸盖菇素衍生物及使用方法 Pending CN116348106A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063073104P 2020-09-01 2020-09-01
US63/073,104 2020-09-01
PCT/CA2021/051209 WO2022047579A1 (en) 2020-09-01 2021-09-01 Halogenated psilocybin derivatives and methods of using

Publications (1)

Publication Number Publication Date
CN116348106A true CN116348106A (zh) 2023-06-27

Family

ID=80492287

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180067808.XA Pending CN116348106A (zh) 2020-09-01 2021-09-01 卤代裸盖菇素衍生物及使用方法

Country Status (10)

Country Link
US (3) US11998557B2 (https=)
EP (1) EP4208445A4 (https=)
JP (1) JP2023539949A (https=)
KR (1) KR20230062595A (https=)
CN (1) CN116348106A (https=)
AU (1) AU2021337466A1 (https=)
CA (1) CA3191102A1 (https=)
IL (1) IL301026A (https=)
MX (1) MX2023002557A (https=)
WO (1) WO2022047579A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114787363A (zh) * 2019-10-01 2022-07-22 恩派瑞安神经科学公司 对真菌进行遗传工程化以调节色胺表达

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230124103A (ko) * 2020-02-18 2023-08-24 길가메쉬 파마슈티컬스, 인코포레이티드 기분 장애 치료에 사용되기 위한 특이적 트립타민
EP4347559A4 (en) * 2021-06-02 2025-04-09 Saint Joseph's University FLUORINATED TRYPTAMINE COMPOUNDS, RELATED ANALOGUES AND METHODS USING THEM
EP4457336A4 (en) 2021-12-31 2026-01-14 Empyrean Neuroscience Inc ORGANISMS GENETICALLY MODIFIED TO PRODUCE PSYCHOTROPIC ALKALOIDS
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
WO2024178504A1 (en) * 2023-02-27 2024-09-06 Enveric Biosciences Canada Inc. Tri-halo-alkoxy-substituted tryptamine derivatives and methods of using
US12157722B1 (en) 2023-08-03 2024-12-03 Gilgamesh Pharmaceuticals, Inc. Crystalline hydrochloride salts of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
US12129234B1 (en) 2023-08-03 2024-10-29 Gilgamesh Pharmaceuticals, Inc. Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
CN121866243A (zh) * 2023-09-07 2026-04-14 耶路撒冷希伯来大学伊森姆研究发展有限公司 致幻化合物、其制备方法及其用途
GB202315025D0 (en) * 2023-09-29 2023-11-15 Psylink Uab Production and medical use of psilocybin and related compounds
WO2025073360A1 (en) 2023-10-04 2025-04-10 Enzyan Biocatalysis Gmbh Biocatalytic cascade for the production of tryptamine derivatives
WO2025189271A1 (en) * 2024-03-15 2025-09-18 Enveric Biosciences Canada Inc. N-heterocycle substituted tryptamine derivatives and methods of using

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0585206A1 (en) * 1992-07-01 1994-03-02 Aldo I.F.L.O. S.a.s. di Giorgio e Laguzzi Tryptamines for treatment of circadian rhythm disorders
CN1409759A (zh) * 1999-12-15 2003-04-09 辛根塔参与股份公司 用于卤化反应的组合物和方法
WO2004085392A1 (en) * 2003-03-25 2004-10-07 Faust Pharmaceuticals Melatonin derivatives and their use for treating neurological dysfunctions
WO2019173797A1 (en) * 2018-03-08 2019-09-12 New Atlas Biotechnologies Llc Processes for the production of tryptamines
WO2019180309A1 (en) * 2018-03-19 2019-09-26 Teknologian Tutkimuskeskus Vtt Oy Heterologous production of psilocybin
WO2021168082A1 (en) * 2020-02-18 2021-08-26 Gilgamesh Pharmaceuticals, Inc. Specific tryptamines for use in the treatment of mood disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688807A (en) * 1994-03-11 1997-11-18 Eli Lilly And Company Method for treating 5HT2B receptor related conditions
CN1148340A (zh) * 1994-03-11 1997-04-23 伊莱利利公司 治疗与5htzb受体有关病症的方法
AU2003249584B9 (en) 2002-06-21 2008-05-15 Suven Life Sciences Limited Arylalkyl indoles having sertonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
US20080171779A1 (en) * 2007-01-16 2008-07-17 Solvay Pharmaceuticals B.V. Use of 5-ht6 antagonists to prevent relapse into addiction
US20090093513A1 (en) * 2007-10-09 2009-04-09 Hamann Mark T Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter
CN104276993B (zh) * 2013-07-12 2019-03-15 广东东阳光药业有限公司 吲哚衍生物及其在药物上的应用
WO2018064465A1 (en) * 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
WO2018106907A1 (en) * 2016-12-08 2018-06-14 Novatarg, Inc. Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therary
MA50786A (fr) 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
JP7093961B2 (ja) * 2018-02-13 2022-07-01 国立大学法人金沢大学 ストレス低減薬剤
CN119954801A (zh) * 2019-07-17 2025-05-09 阿尔维纳斯运营股份有限公司 Tau蛋白靶向化合物及相关使用方法
CA3160793A1 (en) * 2019-12-04 2021-06-10 Neonmind Biosciences Inc. Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder
JP2023540329A (ja) 2020-09-04 2023-09-22 ギルガメッシュ・ファーマシューティカルズ・インコーポレイテッド アゼチジニルトリプタミン及び精神障害を処置する方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0585206A1 (en) * 1992-07-01 1994-03-02 Aldo I.F.L.O. S.a.s. di Giorgio e Laguzzi Tryptamines for treatment of circadian rhythm disorders
CN1409759A (zh) * 1999-12-15 2003-04-09 辛根塔参与股份公司 用于卤化反应的组合物和方法
WO2004085392A1 (en) * 2003-03-25 2004-10-07 Faust Pharmaceuticals Melatonin derivatives and their use for treating neurological dysfunctions
WO2019173797A1 (en) * 2018-03-08 2019-09-12 New Atlas Biotechnologies Llc Processes for the production of tryptamines
WO2019180309A1 (en) * 2018-03-19 2019-09-26 Teknologian Tutkimuskeskus Vtt Oy Heterologous production of psilocybin
WO2021168082A1 (en) * 2020-02-18 2021-08-26 Gilgamesh Pharmaceuticals, Inc. Specific tryptamines for use in the treatment of mood disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAVID E. NICHOL: "Structure–activity relationships of serotonin 5-HT2A agonists", ADVANCED REVIEW, vol. 1, no. 5, 13 August 2012 (2012-08-13), pages 559 - 579, XP055875065, DOI: 10.1002/wmts.42 *
GENBANK: "AHL44344.1", pages 1, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/protein/AHL44344.1?report=genbank&log$=protalign&blast_rank=1&RID=NRNFFW4Y013> *
JOYCE LIU等: "Unusual Acetylation-Dependent Reaction Cascade in the Biosynthesis of the Pyrroloindole Drug Physostigmine", 《ANGEWANDTE CHEMIE》, vol. 53, no. 1, 3 January 2024 (2024-01-03), pages 136 - 139, XP055454320, DOI: 10.1002/anie.201308069 *
LIJIAN DING等: "Discovery and Structure-Based Optimization of 6-Bromotryptamine Derivatives as Potential 5-HT2A Receptor Antagonists", 《MOLECULES》, vol. 20, no. 9, 23 September 2015 (2015-09-23), pages 17675 - 17683, XP055911581, DOI: 10.3390/molecules200917675 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114787363A (zh) * 2019-10-01 2022-07-22 恩派瑞安神经科学公司 对真菌进行遗传工程化以调节色胺表达

Also Published As

Publication number Publication date
EP4208445A1 (en) 2023-07-12
AU2021337466A8 (en) 2023-04-13
WO2022047579A1 (en) 2022-03-10
JP2023539949A (ja) 2023-09-20
EP4208445A4 (en) 2024-10-02
MX2023002557A (es) 2023-05-29
IL301026A (en) 2023-05-01
US20230293558A1 (en) 2023-09-21
KR20230062595A (ko) 2023-05-09
US11998557B2 (en) 2024-06-04
US20250057861A1 (en) 2025-02-20
CA3191102A1 (en) 2022-03-10
AU2021337466A1 (en) 2023-03-30
US20240299427A1 (en) 2024-09-12
US12138276B2 (en) 2024-11-12

Similar Documents

Publication Publication Date Title
CN116348106A (zh) 卤代裸盖菇素衍生物及使用方法
AU2016358063B2 (en) Functional expression of monooxygenases and methods of use
CN108587995B (zh) 用于生产鼠李糖脂的细胞和方法
DK2443163T3 (en) POLYMERIZATION OF ISOPREN FROM RENEWABLE RESOURCES
AU2019375975B2 (en) Artificial expression constructs for selectively modulating gene expression in excitatory cortical neurons
KR20120136349A (ko) 고가의 화학적 생성물의 미생물 생산, 및 관련 조성물, 방법 및 시스템
CN101365788B (zh) Δ-9延伸酶及其在制备多不饱和脂肪酸中的用途
CN110551713B (zh) 用于修饰梭状芽孢杆菌属细菌的优化的遗传工具
KR20140015136A (ko) 3-히드록시프로피온산 및 다른 생성물의 제조 방법
KR20210149060A (ko) Tn7-유사 트랜스포존을 사용한 rna-유도된 dna 통합
KR20110038087A (ko) 재생가능 자원으로부터의 이소프렌 중합체
TW201120204A (en) Fuel compositions comprising isoprene derivatives
KR20110076868A (ko) 분리 조건 및/또는 안전한 작업 범위 하에서의 ｃ5 탄화수소가 없는 이소프렌의 제조 방법 및 조성물
KR20110122672A (ko) 이소프렌 및 공-산물을 제조하는 방법
KR20130027063A (ko) Ｆｅ-ｓ 클러스터 요구성 단백질의 활성 향상
KR20230157342A (ko) 다중 치환기 실로시빈 유도체 및 사용 방법
EP3158073B1 (en) Compositions and methods for making (s)-norcoclaurine and (s)-norlaudanosoline, and synthesis intermediates thereof
KR20130117753A (ko) 포스포케톨라아제를 포함하는 재조합 숙주 세포
DK2623594T3 (da) Antistof mod human prostaglandin-E2-receptor EP4
KR20140092759A (ko) 숙주 세포 및 아이소부탄올의 제조 방법
KR20220012327A (ko) 피토칸나비노이드 및 피토칸나비노이드 전구체의 생산을 위한 방법 및 세포
BRPI0806354A2 (pt) plantas oleaginosas transgências, sementes, óleos, produtos alimentìcios ou análogos a alimento, produtos alimentìcios medicinais ou análogos alimentìcios medicinais, produtos farmacêuticos, bebidas fórmulas para bebês, suplementos nutricionais, rações para animais domésticos, alimentos para aquacultura, rações animais, produtos de sementes inteiras, produtos de óleos misturados, produtos, subprodutos e subprodutos parcialmente processados
KR20120099509A (ko) 재조합 숙주 세포에서 육탄당 키나아제의 발현
KR20090058519A (ko) 안트라닐레이트 신타제의 엽록체를 표적으로 하는 발현에 의한 고-트립토판 옥수수의 생산
AU2018254529B2 (en) Therapeutic genome editing in Wiskott-Aldrich syndrome and X-linked thrombocytopenia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination